Company Focus
GSK
Latest GSK News
Pharmaceutical
South Korea is fast becoming a focal point for global biopharmaceutical licensing, with deal values reaching $7.86 billion year-to-date in 2025, a 113% jump on the previous year, according to GlobalData. The rebound follows a drop in 2024, when total deal value fell to $3.67 billion amid wider economic challenges. 12 August 2025
Related News
Insights
Company Spotlight
A biopharmaceutical company focused on developing tumor infiltrating lymphocyte (TIL) therapies for patients with cancer.
Latest News & Features of interest to GSK
Biotechnology
Swedish biotech Anocca has raised about 440 million Swedish kronor ($46 million) in new financing to accelerate development of VIDAR-1, its gene-edited TCR-T cell therapy targeting mutant KRAS in pancreatic cancer. The funding, led by Mellby Gård with support from AMF, Ramsbury and other investors, will also advance earlier pipeline projects. 18 August 2025
Pharmaceutical
US pharma major Bristol Myers Squibb has appointed Dr Nathan Pennell as senior vice president, worldwide head of medical affairs, hematology and oncology, effective August 18, 2025. 18 August 2025
Pharmaceutical
The European Commission (EC) granted marketing authorization for Ogsiveo (nirogacestat), an oral gamma secretase inhibitor, as monotherapy for the treatment of adults with progressing desmoid tumors who require systemic treatment. 18 August 2025
Biotechnology
The bladder cancer market across the eight major markets (8MM: USA, France, Germany, Italy, Spain, UK, China, and Japan) is projected to grow from $3 billion in 2023 to $16 billion in 2033, at a compound annual growth rate (CAGR) of 18%. 18 August 2025
Pharmaceutical
AstraZeneca has launched FluMist Home, the first FDA-approved influenza vaccine program that allows self- or caregiver administration. FluMist (influenza vaccine live, intranasal) can now be delivered directly to households, making it the first seasonal flu shot available without a trip to the clinic or pharmacy. 18 August 2025
Pharmaceutical
Last week, PureTech Health spun out a new company, Celea Therapeutics, which will develop its pulmonary fibrosis candidate deupirfenidone (LYT-100). The US Food and Drug Administration (FDA) granted approval for Insmed’s Brinsupri (brensocatib) for the treatment of a chronic inflammatory lung condition. Last week also saw US biotech Sarepta Therapeutics selling 9.3 million shares in Arrowhead, raising around $174 million, and transferring around $50 million to Arrowhead. Basilea in-licensed rights to Venatorx’ urinary tract infection candidate ceftibuten-ledaborbactam etzadroxil. 17 August 2025
Pharmaceutical
The Swiss government has met with senior executives from Roche and Novartis to discuss the outlook for the pharmaceutical industry amid escalating US trade measures. 15 August 2025
Pharmaceutical
The US Department of Health and Human Services has reinstated the Task Force on Safer Childhood Vaccines, a panel created by Congress to strengthen the safety, quality and oversight of vaccines given to American children. The original group was disbanded in 1998. 15 August 2025
Biotechnology
The US Food and Drug Administration (FDA) has approved Papzimeos (zopapogene imadenovec-drba) for the treatment of adults with recurrent respiratory papillomatosis (RRP). 15 August 2025
Pharmaceutical
Swiss drug developer Basilea Pharmaceutica has entered into an exclusive license agreement with Venatorx Pharmaceuticals, to acquire the global rights to ceftibuten-ledaborbactam etzadroxil. 15 August 2025
Latest In Brief for GSK
Pharmaceutical
German family-owned pharma major Boehringer Ingelheim announced that Hernexeos (zongertinib tablets) has been recommended as a preferred subsequent therapy option for the treatment of patients with advanced or metastatic non-small cell lung cancer (NSCLC) with ERBB2 (HER2) mutations who received prior systemic therapy in the latest NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for non-small cell lung cancer (Version 8), updated on August 15, 2025 16 August 2025
Latest Relevant Ones To Watch News
Last week, PureTech Health spun out a new company, Celea Therapeutics, which will develop its pulmonary fibrosis candidate deupirfenidone (LYT-100). The US Food and Drug Administration (FDA) granted approval for Insmed’s Brinsupri (brensocatib) for the treatment of a chronic inflammatory lung condition. Last week also saw US biotech Sarepta Therapeutics selling 9.3 million shares in Arrowhead, raising around $174 million, and transferring around $50 million to Arrowhead. Basilea in-licensed rights to Venatorx’ urinary tract infection candidate ceftibuten-ledaborbactam etzadroxil. 17 August 2025
12 August 2025
Relevant Ones to Watch Companies
Refine Search
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze